T3Inh-1|cas:50440-30-7|西域试剂

T3Inh-1

产品编号：Bellancom-125961| CAS NO：50440-30-7| 分子式：C₂₇H₂₀N₆O₃| 分子量：476.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-125961	￥2800.00	杭州北京（现货）
Bellancom-125961	￥4640.00	杭州北京（现货）
Bellancom-125961	￥8800.00	杭州北京（现货）
Bellancom-125961	￥13600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

T3Inh-1

产品介绍

T3Inh-1 是一种有效且选择性的 ppGalNAc-T3 抑制剂(IC₅₀=7 µM)。T3Inh-1 可降低组织细胞和小鼠体内的 FGF23 激素水平，且不会产生任何毒副作用。T3Inh-1 还可以预防乳腺癌细胞。ppGalNAc-T3 酶至少涉及两种重要的医学途径：癌症转移和FGF23的稳定 (调节血液中的磷酸盐水平)。

生物活性

T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC₅₀=7 µM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream).

体外研究

T3Inh-1 (5 µM; 24-48 hours; 5 µM; MDA-MB231 cells) is strikingly effective, inhibiting migration by >80% and invasion by 98% while causing no discernable effect on cell proliferation.
T3Inh-1 exhibits no toxicity and did not affect HEK cell proliferation.
T3Inh-1 (HEK cells; 6 hours)increases cleavage of FGF23.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

T3Inh-1 (25 or 50 mg/kg; i.p.) blocks ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing its cleavage.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type C57BL/6 six to eight week old mice
Dosage:	25 or 50 mg/kg
Administration:	Intraperitoneal injection (Dissolved in DMSO at 25 and 50 mg/ml then further diluted with PEG400 to create 5 and 10 mg/ml stocks for injection)
Result:	Caused a robust and statistically significant increase the ratio of cleaved/intact FGF23 at the tested 25 and 50 mg/kg concentrations.

体内研究

T3Inh-1 (25 or 50 mg/kg; i.p.) blocks ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing its cleavage.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type C57BL/6 six to eight week old mice
Dosage:	25 or 50 mg/kg
Administration:	Intraperitoneal injection (Dissolved in DMSO at 25 and 50 mg/ml then further diluted with PEG400 to create 5 and 10 mg/ml stocks for injection)
Result:	Caused a robust and statistically significant increase the ratio of cleaved/intact FGF23 at the tested 25 and 50 mg/kg concentrations.

性状

Solid

溶解性数据

In Vitro:

DMSO : 10 mg/mL (20.99 mM; ultrasonic and adjust pH to 6 with HCl)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0987 mL	10.4934 mL	20.9868 mL
5 mM	0.4197 mL	2.0987 mL	4.1974 mL
10 mM	0.2099 mL	1.0493 mL	2.0987 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明